Loading viewer...
investor_presentation
Format: PDF investor_presentation
1 Educational Briefing On Interference Proceedings Relating To CRISPR/Cas9 Genome Editing Technology Patents August 28, 2018
Educational Briefing On
Interference Proceedings Relating To
CRISPR/Cas9 Genome Editing
Today’s Participants
•Cora Holt, Associate, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
•José Rivera, Executive Vice President and General Counsel, Intellia Therapeutics
•Lindsey Trickett, Vice President, Investor Relations, Intellia Therapeutics3
Intellia Therapeutics Legal Disclaimers
This presentation contains “forward -looking statements” ofIntellia Therapeutics, Inc.(“Intellia”) within themeaning
ofthePrivate Securities Litigation Reform Actof1995 .These forward -looking statements include, butarenot
limited to,express orimplied statements regarding thepatent interference proceedings between theUniversity of
California Berkeley andtheBroad Institute ;thescope oftheclaims covered bythepatent applications filed bythe
University ofCalifornia Berkeley andtheBroad Institute ;thedecision bytheU.S.Court ofAppeals fortheFederal
Circuit regarding thepatent interference proceedings between theUniversity ofCalifornia Berkeley andtheBroad
Institute andpotential next steps after adecision isrendered bytheU.S.Court ofAppeals fortheFederal Circuit ;
Intellia’s ability toadvance andexpand theCRISPR/Cas 9technology todevelop intohuman therapeutic products,
aswellasourCRISPR/Cas 9intellectual property portfolio ;ourability toachieve stable oreffective genome editing ;
andtheintellectual property position andstrategy ofIntellia’s licensors orother parties from which itderives rights .
Anyforward -looking statements inthispresentation arebased onmanagement’s current expectations andbeliefs
offuture events, and aresubject toanumber ofrisks and uncertainties that could cause actual results todiffer
materially and adversely from those setforth inorimplied bysuch forward -looking statements .These risks and
uncertainties include, butarenotlimited torisks related toIntellia’s ability toprotect and maintain ourintellectual
property position andrisks related totheability ofourlicensors toprotect andmaintain their intellectual property
position .Foradiscussion ofthese and other risks and uncertainties, and other important factors, anyofwhich
could cause Intellia’s actual results todiffer from those contained intheforward -looking statements, see the
section entitled “Risk Factors” inIntellia’s most recent annual report onForm 10-Kandquarterly reports onForm
10-Qfiled with theSecurities andExchange Commission, aswell asdiscussions ofpotential risks, uncertainties,
andother important factors inIntellia’s other filings with theSecurities andExchange Commission .Allinformation
inthispresentation isasofthedate oftherelease, andIntellia Therapeutics, Inc.undertakes noduty toupdate this
information unless required bylaw.4
Preview truncated — download the full document for the complete content.
investor_presentation
84 Pages
investor_presentation
27 Pages
Adani Ports and SEZ Limited
investor_presentation
Enbridge
Singtel Digital Transformation 2018
investor_presentationinvestor_presentation
23 Pages
Singapore Telecommunications Limited